Stock Research: Nektar

Peer-based, data-driven stock research by Obermatt enables quick and easy due diligence for your stock investing.

Nektar

NasdaqGS:NKTR US6402681083
35
  • Value
    82
  • Growth
    65
  • Safety
    Safety
    6
  • Combined
    53
  • Sentiment
    34
  • 360° View
    360° View
    35
Unlock
Which ranks are driving this 360° View?
Subscribe to View
Company Description

Nektar Therapeutics is a clinical-stage biotechnology company developing treatments for immunological dysfunction in autoimmune and chronic inflammatory diseases and oncology. The company focuses on medicines targeting biological pathways to stimulate the immune response to fight cancer. Nektar Therapeutics operates in the biotechnology industry. In the last fiscal year, the company had $400 million in market cap, profits of $68 million, revenue of $98 million, and 61 employees.

more
Analysis

ANALYSIS: With an Obermatt 360° View of 35 (better than 35% compared with alternatives), overall professional sentiment and financial characteristics for the stock Nektar are below the industry average. The 360° View is based on consolidating four consolidated indicators, with half of the metrics below and half above average for Nektar. The consolidated Growth Rank has a good rank of 65, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth as well as stock returns. This means that growth is higher than for 65% of competitors in the same industry. In addition, the consolidated Safety Rank has a safer rank of 82 which means that the company has a financing structure that is safer than 82% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. But the consolidated Value Rank has a less desirable rank of 6 which means that the share price of Nektar is on the higher side compared with typical size in indicators such as revenues, profits, and invested capital. This means that the stock price is higher than for 94% of alternative stocks in the same industry. The consolidated Sentiment Rank also has a low rank of 34, which means that professional investors are more pessimistic about the stock than for 66% of alternative investment opportunities. ...read more

more
Index
NASDAQ
D.J. US Pharmaceutical
S&P MIDCAP
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 21-Aug-2025.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Value
Identifies how good a value the stock is.
Good Value Expensive
Growth
Shows a company's growth potential.
High Growth Tough Times
Safety
Safety
Assesses how financially secure a company is.
Well-Financed High Leverage
Combined
Consolidated view across Value, Growth, and Safety.
Good Tread Carefully
Sentiment
Shows what the market thinks of a stock.
Positive Sentiment Skepticism
360° View
360° View
Holistic stock analysis: all key non-/financial metrics
Good Watch Out

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
6 22 77 21
Growth
65 73 39 75
Safety
Safety
82 93 94 77
Sentiment
34 16 4 20
360° View
360° View
35 49 60 42
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Analyst Opinions
80 17 1 29
Opinions Change
42 50 50 50
Pro Holdings
n/a 70 19 78
Market Pulse
11 15 13 14
Sentiment
34 16 4 20
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
6 22 77 21
Growth
65 73 39 75
Safety Safety
82 93 94 77
Combined
53 81 93 60
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Price vs. Sales (P/S)
81 81 81 8
Price vs. Earnings (P/E)
5 49 74 14
Price vs. Book (P/B)
14 28 81 42
Dividend Yield
1 1 1 1
Value
6 22 77 21
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Revenue Growth
8 4 6 97
Profit Growth
17 71 66 25
Capital Growth
100 85 100 85
Stock Returns
81 87 5 43
Growth
65 73 39 75
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Leverage
100 100 100 100
Refinancing
57 92 100 71
Liquidity
27 25 22 11
Safety Safety
82 93 94 77

Similar Stocks

Discover high‑ranked alternatives to Nektar and broaden your portfolio horizons.

Micron

NasdaqGS:MU
Country: USA
Industry: Semiconductors
Size: X-Large
Full Stock Analysis

Meta

NasdaqGS:FB
Country: USA
Industry: Interactive Media & Services
Size: XX-Large
Full Stock Analysis

Alphabet

NasdaqGS:GOOG.L
Country: USA
Industry: Interactive Media & Services
Size: XX-Large
Full Stock Analysis

Lithia Motors

NYSE:LAD
Country: USA
Industry: Automotive Retail
Size: X-Large
Full Stock Analysis

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.